Resultado de búsqueda
30 de nov. de 2015 · β-Blockers are less effective in reducing central than peripheral systolic blood pressure. This effect is less pronounced with vasodilating than with nonvasodilating β-blockers, although the difference is mostly explained by a lower reduction in heart rate with the former.
22 de abr. de 2015 · This study describes the differences in metabolic and anti-inflammatory of a vasodilating (nebivolol) and non- vasodilating (metoprolol) drugs. It highlights the unique property of nebivolol as a vasodilating BB via NO mediated mechanisms .
Vasodilators have been shown to be of particular benefit in both blood pressure control and other cardiometabolic components with limited disturbance in metabolic parameters. Nebivolol, a third-generation beta-blocker (BB), acts by increasing nitric oxide (NO) bioavailability.
11 de may. de 2023 · The pathophysiology of hypertension suggest that non vasodilating β-blockers are preferred, as first-line, in young/middle aged hypertensive patients (< 60 years), to decrease sympathetic hyperactivity and consequently high BP, while vasodilating b-blockers, are most appropriate, as first choice, in elderly patients (> 60 years ...
9 de jun. de 2021 · Abstract. Bisoprolol and nebivolol are highly selective β 1 -adrenoceptor antagonists, with clinical indications in many countries within the management of heart failure with reduced left ventricular ejection fraction (HFrEF), ischaemic heart disease (IHD), and hypertension.
Whether this effect is less pronounced with vasodilating β-blockers (VBB) when compared with nonvasodilating β-blockers (NVBB) remains unsettled. We conducted a systematic review and meta-analysis of randomized trials exploring the effects of β-blockers on both pSBP and cSBP in hypertension.
29 de mar. de 2017 · Compared with traditional β-blockers, newer agents with β 1 selectivity or vasodilating properties (such as carvedilol or nebivolol) reduce central pulse pressure and aortic stiffness more effectively than atenolol or metoprolol and tend to have fewer metabolic side effects [ 2 ]. Table 1. Characteristics of commonly used β-blockers.
